T
Thomas Glaab
Researcher at Boehringer Ingelheim
Publications - 43
Citations - 2514
Thomas Glaab is an academic researcher from Boehringer Ingelheim. The author has contributed to research in topics: COPD & Tiotropium bromide. The author has an hindex of 23, co-authored 41 publications receiving 2342 citations. Previous affiliations of Thomas Glaab include Hannover Medical School & Fraunhofer Society.
Papers
More filters
Journal ArticleDOI
Tiotropium versus Salmeterol for the Prevention of Exacerbations of COPD
Claus Vogelmeier,Bettina Hederer,Thomas Glaab,Hendrik Schmidt,Maureen P.M.H. Rutten-van Mölken,Kai M. Beeh,Klaus F. Rabe,Leonardo M. Fabbri +7 more
TL;DR: Results show that, in patients with moderate-to-very-severe COPD, tiotropium is more effective than salmeterol in preventing exacerbations.
Journal ArticleDOI
Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease.
TL;DR: This study demonstrates that combination therapy with salmeterol/fluticasone compared with Salmeterol monotherapy significantly reduces the frequency of moderate/severe exacerbations in patients with severe COPD.
Journal ArticleDOI
Invasive and noninvasive methods for studying pulmonary function in mice
TL;DR: Current set of invasive and noninvasive methods of measuring murine pulmonary function, with particular emphasis on practical considerations that should be considered when applying them for phenotyping in the laboratory mouse are reviewed.
Journal ArticleDOI
Outcome measures in chronic obstructive pulmonary disease (COPD): strengths and limitations
TL;DR: In this article, a review of the current methods for assessing clinical outcomes in COPD mainly rely on physiological tests combined with the use of questionnaires is presented, with particular emphasis on their limitations and opportunities to be recognized when assessing and interpreting their use in clinical trials of COPD.
Journal ArticleDOI
Pharmacological Targeting of Anaphylatoxin Receptors during the Effector Phase of Allergic Asthma Suppresses Airway Hyperresponsiveness and Airway Inflammation
Ralf Baelder,Barbara Fuchs,Wilfried Bautsch,Joerg Zwirner,Jörg Köhl,Heinz G. Hoymann,Thomas Glaab,Veit J. Erpenbeck,Norbert Krug,Armin Braun +9 more
TL;DR: An important and exclusive role for C5aR signaling on the development of airway hyperresponsiveness during pulmonary allergen challenge is suggested, whereas both anaphylatoxins contribute to airway inflammation and IL-4 production.